Share this Job

Clinical Veterinary Surgeon

Req ID:  42863

Tranent, ELN, GB

For 70 years, Charles River employees have worked together to assist in the discovery, development and safe manufacture of new drug therapies. When you join our family, you will have a significant impact on the health and well-being of people across the globe. Whether your background is in life sciences, finance, IT, sales or another area, your skills will play an important role in the work we perform. In return, we’ll help you build a career that you can feel passionate about.

Job Summary


We are seeking a Clinical Veterinary Surgeon for our Safety Assesment site located Tranent.

You will act as a deputy Named Veterinary Surgeon providing clinical care service to the broad range of laboratory and farm animal species on our site in Tranent.  You will assist in the conduct of studies in veterinary fields such as surgery, ophthalmology and clinical examinations.  

The following are minimum qualifications related to the Clinical Veterinary Surgeon position:

Membership of the Royal College of Veterinary Surgeons is essential.

You will have graduated with a Veterinary degree and have good observational and fine motor skills with the ability to communicate effectively with internal and external clients.  Previous experience of working in general practice, or particularly as a Named Veterinary Surgeon or deputy at a designated establishment, is sought.  

Experience with laboratory animals and knowledge of the Animals (Scientific Procedures) Act 1986 would be an advantage, but not essential as training will be provided.  You will have established skills in surgery and anaesthesia, and will have a desire to improve the welfare of the animals in your care.  Participation in an out of hours on-call rota will be required although this is not onerous.  

In return we offer a competitive salary and benefits package and a real commitment to your training and development needs.



About Safety Assessment
Charles River is committed to helping our partners expedite their preclinical drug development with exceptional safety assessment services, state-of-the-art facilities and expert regulatory guidance. From individual specialty toxicology and IND enabling studies to tailored packages and total laboratory support, our deeply experienced team can design and execute programs that anticipate challenges and avoid roadblocks for a smooth, efficient journey to market.  Each year approximately 120 investigational new drug (IND) programs are conducted in our Safety Assessment facilities.


About Charles River
Charles River is an early-stage contract research organization (CRO). We have built upon our foundation of laboratory animal medicine and science to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, to support clients from target identification through preclinical development. Charles River also provides a suite of products and services to support our clients’ clinical laboratory testing needs and manufacturing activities. Utilizing this broad portfolio of products and services enables our clients to create a more flexible drug development model, which reduces their costs, enhances their productivity and effectiveness to increase speed to market.


With over 13,000 employees within 80 facilities in 23 countries around the globe, we are strategically positioned to coordinate worldwide resources and apply multidisciplinary perspectives in resolving our client’s unique challenges.  Our client base includes global pharmaceutical companies, biotechnology companies, government agencies and hospitals and academic institutions around the world.


At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guide us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe. We have proudly supported the development of 80% of the drugs approved by the FDA in 2017.


For more information, please visit